Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biogen
7
×
boston blog main
boston top stories
7
×
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
fda
7
×
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
7
×
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
clinical trials
eli lilly
novartis
alzheimer's disease
amgen
bristol-myers squibb
cancer
gene therapy
glaxosmithkline
ipo
medicare
What
bio
roundup
ipo
biogen
biotech
crispr
days
drug
fda
new
week
activity
administration
alliance
allogene
alzheimer’s
america
angry
annual
anti
approvals
assessed
attention
august
benefited
bristol
busy
buy
calls
cancer
changing
clamped
color
communities
conference
continues
convoluted
covid
decisions
delays
Language
unset
Current search:
biogen
×
" san diego blog main "
×
" boston top stories "
×
fda
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
Bio Roundup: Head and Spine Previews, Biogen Moves, IPO Dreams & More
@xconomy.com
5 years ago
Losing “Scalps”? Despite Pharma Fear, A Split on Trump Rx-Price Plans
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More